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Background
The HS-1 associated protein X-1 (HAX-1) is a ubiqui-
tously expressed protein that protects cardiomyocytes
from programmed cell death. HAX-1 is mainly located in
cardiac mitochondria and sarcoplasmic reticulum.
Recently, it has been recognized that HAX-1 serves as a
binding partner of phospholamban, which plays a funda-
mental role in controlling basal contractility and constitu-
tes a key downstream effector of the b-adrenergic
signaling cascade. However, the functional significance of
HAX-1 in the heart remains unclear. Our previous studies
have shown that overexpression of HAX-1 in vitro or in
vivo by adenoviruses and transgenesis reduced cardiac
myocyte contractility and calcium transients under basal
condition without significant alterations of isoproterenol
response. Conversely, in vitro downregulation of HAX-1
enhanced calcium kinetics and mechanics under basal
conditions.
Methods and results
To further investigate the role of the endogenous HAX-1
in the cardiac contractile function, HAX-1 heterozygous
deficient mice with 36% of HAX-1 expression in the heart
were characterized, since the homozygous mice are lethal
at 5-12 weeks afterbirth. Interestingly, in vivo echocardio-
graphy showed that decreased HAX-1 expression was
associated with significantly enhanced cardiac perfor-
mance, including fractional shortening and ejection frac-
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Figure 1 WT: Wild type, HAX-1 KO HE: HAX-1 knockout heterozygous. A: EF% (percentage of ejection fraction) and FS% (percentage of fractional
shortening) by echocardiography; B: Rates of contraction (+dp/dt) and relaxation (-dp/dt) by Langendorff perfusion. *: P<0.05, compared with
WT.
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tion, when compared to age-matched wild types. Ex-vivo
Langendorff perfusion suggested markedly increased rates
of contraction and relaxation, compared to wild types
(Figure 1). Furthermore, at the cardiomyocyte levels, we
also found similar cardiac phenotype with elevated frac-
tional shortening, rates of contraction and relaxation as
well as calcium kinetics under basal conditions. The func-
tional improvement in the heterozygous HAX-1 deficient
mouse hearts does not plays a role in the expressions of
major SR calcium handling proteins, including: SERCA2a,
calsequestrin and phospholamban. However, the affinity of
SERCA2 for calcium was significantly increased without
alteration of maximal velocity of this calcium pump. The
enhanced cardiac contractility is not related to any signifi-
cant cardiac remodeling and histology changes at the age
of 10-12 weeks.
Conclusion
These results indicate that decreased HAX-1 expression in
the heart is associated with increased cardiac contractility
and calcium handling, suggesting that HAX-1 may be a
novel regulator in cardiac contractile performance.
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